Message :
Required fields
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.